Firstly, considering the site of irAE manifestation, studies have demonstrated36 that different immune checkpoint inhibitors exhibit distinct toxicity profiles; for instance, CTLA‐4 inhibitors commonly result in colitis, encephalitis, and rash at various levels. The gene discussed is CTLA4; the disease is viral encephalitis.